Research Analysts Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Investment analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Wednesday, February 26th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.43) per share for the quarter, down from their prior forecast of ($0.29). Wedbush currently has a "Outperform" rating and a $32.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.21 EPS and FY2028 earnings at $1.24 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million.

Several other analysts have also recently weighed in on DAWN. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, February 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright dropped their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Bank of America decreased their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Finally, TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $34.86.

Remove Ads

Day One Biopharmaceuticals Trading Up 4.2 %

Shares of Day One Biopharmaceuticals stock traded up $0.35 on Friday, reaching $8.60. The stock had a trading volume of 2,535,279 shares, compared to its average volume of 1,151,898. The business's 50 day moving average is $12.07 and its two-hundred day moving average is $13.33. Day One Biopharmaceuticals has a 1 year low of $8.02 and a 1 year high of $18.07. The company has a market cap of $871.65 million, a P/E ratio of -8.35 and a beta of -1.46.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after acquiring an additional 1,002 shares during the period. SteelPeak Wealth LLC lifted its position in shares of Day One Biopharmaceuticals by 9.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company's stock worth $242,000 after purchasing an additional 1,550 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of Day One Biopharmaceuticals by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company's stock valued at $346,000 after purchasing an additional 1,805 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Day One Biopharmaceuticals by 5.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company's stock valued at $454,000 after buying an additional 1,894 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Day One Biopharmaceuticals in the fourth quarter worth about $27,000. 87.95% of the stock is currently owned by institutional investors.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company's stock, valued at $1,531,059.40. This represents a 8.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the transaction, the insider now owns 1,034,015 shares in the company, valued at $13,762,739.65. The trade was a 2.82 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,064 shares of company stock valued at $651,225. Insiders own 8.40% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.